Trial Profile
A Phase II Study of Obinutuzumab (GA-101) in Combination With Ibrutinib (I) for the Treatment of Relapsed Mantle Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 08 Jul 2021 Status changed from recruiting to completed.
- 24 Apr 2020 Planned primary completion date changed from 1 Jul 2021 to 1 Dec 2022.
- 23 Nov 2016 Status changed from not yet recruiting to recruiting.